Frontline Immunotherapy on the Horizon in Bladder Cancer – OncLive
|
Frontline Immunotherapy on the Horizon in Bladder Cancer
OncLive Additionally, while the success of immunotherapy has made a significant mark in the field, an unmet need still lies in the fact that these agents only provide a clinical benefit for approximately 1 out of every 3 patients, adds Yu, a professor in the … |
